片頭痛治療薬の世界市場レポート 2025年

片頭痛治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.8％で、72億2,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、遠隔医療と遠隔診察、ヘルスケア政策と保険適用、世界の片頭痛負担の増加、併用療法に起因すると考えられます。予測期間の主な動向には、標的治療、遠隔医療と遠隔診察、患者中心のアプローチ、デジタル治療、片頭痛治療におけるバイオシミラー、臨床研究と臨床試験が含まれます。

片頭痛治療薬市場の予想成長は、女性人口の増加によって促進されると予想されます。特定の期間における各国・地域のあらゆる年齢層の女性を含む女性人口は、片頭痛治療薬の需要を促進する上で重要な役割を果たしています。片頭痛の有病率は男性に比べて女性の方が顕著に高く、遺伝的、ホルモン的、環境的要因の組み合わせが影響しています。国連が発表したWorld Population Prospects 2022によると、2022年現在、世界の女性人口は40億人と推定され、世界人口の49.75％を占めています。予測によれば、2049年には女性の数が男性を上回るといいます。その結果、女性人口の拡大が片頭痛治療薬市場成長の重要な促進要因となっています。

片頭痛の有病率の増加は、今後数年間の片頭痛治療薬市場の成長にさらに貢献すると予想されます。片頭痛は、脳の片側が脈打つような、ドキドキするような痛みが繰り返し起こるのが特徴で、その有病率が高まっているため、効果的な片頭痛治療薬の需要が高まっています。この急増は、拡大する患者集団のニーズに対応する治療法を製薬会社が開発・提供することで、技術革新と売上高の伸びを促進します。例えば、オーストラリア財務省が2023年3月に発表した「Migraine Australia 2022-23 Pre-Budget Submissions」（片頭痛オーストラリア2022-23年予算提出前予算）によると、オーストラリアは世界的に見ても片頭痛の有病率が最も高い国の一つであり（28%）、4人に1人が片頭痛に悩まされています。この有病率は、2型糖尿病、てんかん、喘息の合計を上回る。したがって、片頭痛の有病率の増加は、片頭痛治療薬市場の成長にとって重要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界片頭痛治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の片頭痛治療薬市場：成長率分析
• 世界の片頭痛治療薬市場の実績：規模と成長, 2019-2024
• 世界の片頭痛治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界片頭痛治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の片頭痛治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリプタン
• ベータ遮断薬
• アンジオテンシン遮断薬
• 三環系抗うつ薬
• 抗けいれん薬
• 世界の片頭痛治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他のルート
• 世界の片頭痛治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 小売薬局
• オンライン薬局
• その他のエンドユーザー
• 世界の片頭痛治療薬市場、トリプタンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スマトリプタン
• リザトリプタン
• ゾルミトリプタン
• エレトリプタン
• 世界の片頭痛治療薬市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロプラノロール
• メトプロロール
• チモロール
• 世界の片頭痛治療薬市場アンジオテンシン遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カンデサルタン
• ロサルタン
• 世界の片頭痛治療薬市場、三環系化合物のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アミトリプチリン
• ノルトリプチリン
• 世界の片頭痛治療薬市場抗てんかん薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トピラマート
• バルプロ酸

第7章 地域別・国別分析

• 世界の片頭痛治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の片頭痛治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 片頭痛治療薬市場：競合情勢
• 片頭痛治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Sanofi SA
• Novartis AG
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Dr Reddys Laboratories Ltd.
• H. Lundbeck A/S
• Amneal Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 片頭痛治療薬市場2029：新たな機会を提供する国
• 片頭痛治療薬市場2029：新たな機会を提供するセグメント
• 片頭痛治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Migraine drugs are medications designed to address a neurological condition characterized by intense, throbbing headaches. These drugs operate by targeting various physiological mechanisms responsible for causing migraines.

The primary classes of migraine drugs include triptans, beta-blockers, angiotensin blockers, tricyclics, and anticonvulsants. Triptans, for example, work by altering blood circulation in the brain and modulating how the brain processes pain signals. These drugs can be administered through various routes, such as oral or injectable, and are utilized by diverse end-users, including hospitals and clinics, retail pharmacies, online pharmacies, and others.

The migraine drugs market research report is one of a series of new reports from The Business Research Company that provides migraine drugs market statistics, including migraine drugs industry global market size, regional shares, competitors with a migraine drugs market share, detailed migraine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the migraine drugs industry. This migraine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine drugs market size has grown strongly in recent years. It will grow from $5.38 billion in 2024 to $5.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.

The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.

The anticipated growth of the migraine drugs market is expected to be propelled by the increasing female population. The female population, encompassing females across all age groups in each country or region during a specific period, plays a crucial role in driving the demand for migraine medications. The prevalence of migraines is notably higher in the female population compared to males, influenced by a combination of genetic, hormonal, and environmental factors. As of 2022, according to the World Population Prospects 2022 released by the United Nations, the global female population is estimated at 4.00 billion, constituting 49.75% of the world population. Projections suggest that females will outnumber males by the year 2049. Consequently, the expanding female population serves as a key driver behind the growth of the migraine drugs market.

The increase in the prevalence of migraines is expected to further contribute to the growth of the migraine drug market in the coming years. Migraine headaches, characterized by recurring episodes of pulsing and pounding pain on one side of the brain, have become more prevalent, leading to a rising demand for effective migraine medications. This surge in prevalence fuels innovation and sales growth as pharmaceutical companies develop and provide therapies to address the needs of an expanding patient population. For instance, as reported in March 2023 by the Migraine Australia 2022-23 Pre-Budget Submissions, a document released by the Australian Treasury, Australia has one of the highest migraine rates globally (28%), affecting one in every four people. This prevalence surpasses that of type 2 diabetes, epilepsy, and asthma combined. Therefore, the increasing prevalence of migraines stands as a significant driver for the growth of the migraine drug market.

Major companies operating in the migraine drugs market are concentrating on the development of innovative products to enhance patient care and gain a competitive advantage. One such example is Zavzpret, a nasal spray medication designed for the acute treatment of migraines with or without aura in adults. For example, in March 2023, Pfizer, a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. Targeting the calcitonin gene-related peptide (CGRP), Zavzpret offers a new treatment option, particularly for individuals experiencing migraines with nausea and vomiting, as well as for those unable to use triptans due to cardiovascular risks.

In May 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired BioHaven Pharmaceutical Holding Company Ltd. for $11.6 billion. Through this acquisition, Pfizer aims to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraines. This strategic move underscores the pharmaceutical industry's commitment to advancing migraine drug development and addressing patient needs.

Major companies operating in the migraine drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., AbbVie Inc., Sanofi SA, Novartis AG, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Dr Reddy's Laboratories Ltd., H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Neurelis Inc., ALDER BIOPHARMACEUTICALS INC., eNeura Inc., Winston Pharmaceuticals Ltd.

North America was the largest region in the migraine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the migraine drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the migraine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine drugs market consists of sales of analgesics, ergotamines, sumatriptan, and rizatriptan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for migraine drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Triptans; Betablockers; Angiotensin Blockers; Tricyclics; Anticonvulsants
• 2) By Route of Administration: Oral; Injectable; Other Routes
• 3) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy; Other End Users
• Subsegments:
• 1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
• 2) By Beta Blockers: Propranolol; Metoprolol; Timolol
• 3) By Angiotensin Blockers: Candesartan; Losartan
• 4) By Tricyclics: Amitriptyline; Nortriptyline
• 5) By Anticonvulsants: Topiramate; Valproate
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Bayer AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Migraine Drugs Market Characteristics

3. Migraine Drugs Market Trends And Strategies

4. Migraine Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Migraine Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Migraine Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Migraine Drugs Market Growth Rate Analysis
• 5.4. Global Migraine Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Migraine Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Migraine Drugs Total Addressable Market (TAM)

6. Migraine Drugs Market Segmentation

• 6.1. Global Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptans
• Betablockers
• Angiotensin Blockers
• Tricyclics
• Anticonvulsants
• 6.2. Global Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes
• 6.3. Global Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacy
• Online Pharmacy
• Other End Users
• 6.4. Global Migraine Drugs Market, Sub-Segmentation Of Triptans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sumatriptan
• Rizatriptan
• Zolmitriptan
• Eletriptan
• 6.5. Global Migraine Drugs Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Propranolol
• Metoprolol
• Timolol
• 6.6. Global Migraine Drugs Market, Sub-Segmentation Of Angiotensin Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Candesartan
• Losartan
• 6.7. Global Migraine Drugs Market, Sub-Segmentation Of Tricyclics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amitriptyline
• Nortriptyline
• 6.8. Global Migraine Drugs Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topiramate
• Valproate

7. Migraine Drugs Market Regional And Country Analysis

• 7.1. Global Migraine Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Migraine Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Migraine Drugs Market

• 8.1. Asia-Pacific Migraine Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Migraine Drugs Market

• 9.1. China Migraine Drugs Market Overview
• 9.2. China Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Migraine Drugs Market

• 10.1. India Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Migraine Drugs Market

• 11.1. Japan Migraine Drugs Market Overview
• 11.2. Japan Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Migraine Drugs Market

• 12.1. Australia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Migraine Drugs Market

• 13.1. Indonesia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Migraine Drugs Market

• 14.1. South Korea Migraine Drugs Market Overview
• 14.2. South Korea Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Migraine Drugs Market

• 15.1. Western Europe Migraine Drugs Market Overview
• 15.2. Western Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Migraine Drugs Market

• 16.1. UK Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Migraine Drugs Market

• 17.1. Germany Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Migraine Drugs Market

• 18.1. France Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Migraine Drugs Market

• 19.1. Italy Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Migraine Drugs Market

• 20.1. Spain Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Migraine Drugs Market

• 21.1. Eastern Europe Migraine Drugs Market Overview
• 21.2. Eastern Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Migraine Drugs Market

• 22.1. Russia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Migraine Drugs Market

• 23.1. North America Migraine Drugs Market Overview
• 23.2. North America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Migraine Drugs Market

• 24.1. USA Migraine Drugs Market Overview
• 24.2. USA Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Migraine Drugs Market

• 25.1. Canada Migraine Drugs Market Overview
• 25.2. Canada Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Migraine Drugs Market

• 26.1. South America Migraine Drugs Market Overview
• 26.2. South America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Migraine Drugs Market

• 27.1. Brazil Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Migraine Drugs Market

• 28.1. Middle East Migraine Drugs Market Overview
• 28.2. Middle East Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Migraine Drugs Market

• 29.1. Africa Migraine Drugs Market Overview
• 29.2. Africa Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Migraine Drugs Market Competitive Landscape And Company Profiles

• 30.1. Migraine Drugs Market Competitive Landscape
• 30.2. Migraine Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Migraine Drugs Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Sanofi SA
• 31.3. Novartis AG
• 31.4. AstraZeneca
• 31.5. Abbott Laboratories
• 31.6. GlaxoSmithKline plc.
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Otsuka Holdings Co. Ltd.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Bausch Health Companies Inc.
• 31.12. Eisai Co. Ltd.
• 31.13. Dr Reddys Laboratories Ltd.
• 31.14. H. Lundbeck A/S
• 31.15. Amneal Pharmaceuticals Inc.

32. Global Migraine Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Drugs Market

34. Recent Developments In The Migraine Drugs Market

35. Migraine Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Migraine Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Migraine Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Migraine Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer